Stocktoria
Vivos Therapeutics, Inc. VVOS
Vivos Therapeutics, Inc. (VVOS) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $17.4M at a -121.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.37 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VVOS | Vivos Therapeutics, Inc. | 2/9 | — | — | +16% |
| PROF | Profound Medical Corp. | 5/9 | -3.44 | — | +50.7% |
| NEPH | NEPHROS INC | 6/9 | — | 32.8 | +32.7% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| DRIO | DarioHealth Corp. | 3/9 | -12.4 | — | -17.3% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
FAQ
Is VVOS financially healthy?
Vivos Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does VVOS pay a dividend?
No, Vivos Therapeutics, Inc. does not currently pay a dividend.
How profitable is VVOS?
In FY2025, Vivos Therapeutics, Inc. had a net margin of -121.4%.
What is the analyst price target for VVOS?
The average Wall-Street price target for Vivos Therapeutics, Inc. is $2.45, about 756.6% above the recent price, from 3 analysts.
Is VVOS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vivos Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.